2.99

4.91% 0.14

After Hours: 3.04 0.05 +1.67%

Chimerix Inc (CMRX)

Overview News Price History Option Chain Financials Discussions Forecast

Chimerix Inc stock is traded at $2.99, with a volume of 2.45M. It is up +4.91% in the last 24 hours and up +239.77% over the past month. Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.

Previous Close:

$2.85

Open:

$2.85

24h Volume:

2.45M

Relative Volume:

0.68

Market Cap:

$268.91M

Revenue:

$324.00K

Net Income/Loss:

$-82.10M

P/E Ratio:

1.4515

EPS:

2.06

Net Cash Flow:

$-69.18M

1W Performance:

+1.36%

1M Performance:

+239.77%

6M Performance:

+235.96%

1Y Performance:

+218.09%

1-Day Range:

$2.8005

$3.20

1-Week Range:

$2.705

$3.20

52-Week Range:

$0.75

$3.39

Chimerix Inc Stock (CMRX) Company Profile

Name

Chimerix Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

919.806.1074

Address

2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC

Employee

Twitter

@chimerix

Next Earnings Date

2024-11-07

Latest SEC Filings

CMRX's Discussions on Twitter

Compare CMRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CMRX Chimerix Inc	2.99	268.91M	324.00K	-82.10M	-69.18M	-0.93
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Chimerix Inc Stock (CMRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-23-23	Initiated	Robert W. Baird	Outperform
Sep-07-22	Initiated	CapitalOne	Overweight
Apr-29-21	Initiated	Maxim Group	Buy
Apr-23-21	Resumed	Cowen	Outperform
Mar-31-21	Initiated	Jefferies	Buy
Mar-31-21	Initiated	Wedbush	Outperform
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Feb-02-18	Initiated	H.C. Wainwright	Buy
Aug-09-16	Reiterated	FBR Capital	Mkt Perform
Feb-23-16	Downgrade	Barclays	Overweight → Equal Weight
Feb-23-16	Reiterated	FBR Capital	Mkt Perform
Feb-23-16	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Feb-22-16	Downgrade	Citigroup	Buy → Neutral
Dec-29-15	Downgrade	JP Morgan	Overweight → Neutral
Dec-28-15	Downgrade	FBR Capital	Outperform → Mkt Perform
Dec-28-15	Reiterated	Piper Jaffray	Overweight
Dec-17-15	Initiated	UBS	Buy
Oct-05-15	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-03-15	Initiated	Citigroup	Buy
Aug-18-15	Initiated	FBR Capital	Outperform
Aug-06-15	Reiterated	Brean Capital	Buy
May-11-15	Reiterated	Brean Capital	Buy
Mar-04-15	Initiated	Barclays	Overweight
Feb-12-15	Reiterated	Stifel	Buy
Dec-31-14	Reiterated	Brean Capital	Buy
Jul-08-14	Resumed	Brean Capital	Buy

View All

Chimerix Inc Stock (CMRX) Latest News

Dec 16, 2024

Chimerix, Inc. (NASDAQ:CMRX) Sees Significant Drop in Short Interest - MarketBeat

Dec 16, 2024

Biodefense Market CAGR of 7.3% Size, Growth Drivers and Forecast 2024-2031 | XOMA corporation, Altimmune Inc., - EIN News

Dec 16, 2024

Dec 14, 2024

Drugmaker seeks accelerated breakthrough for brain cancer treatment - The Business Journals

Dec 13, 2024

Wedbush Analysts Reduce Earnings Estimates for Chimerix - MarketBeat

Dec 13, 2024

Dec 12, 2024

Wedbush Brokers Lower Earnings Estimates for Chimerix - MarketBeat

Dec 12, 2024

3 Penny Stocks to Watch Now, 12/12/24 - TipRanks

Dec 12, 2024

Dec 11, 2024

Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy (NASDAQ:CMRX) - Seeking Alpha

Dec 11, 2024

Chimerix (NASDAQ:CMRX) Earns Buy Rating from HC Wainwright - MarketBeat

Dec 11, 2024

Chimerix stock touches 52-week high at $2.20 amid market fluctuations - Investing.com Canada

Dec 11, 2024

Dec 10, 2024

Chimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Can - GuruFocus.com

Dec 10, 2024

3 Promising Penny Stocks With Market Caps Under $2B In US - Simply Wall St

Dec 10, 2024

Chimerix Stock Draws Heavy Retail Chatter After Landing Price-Target Hike On FDA Submission Plan For Cancer Dr - Asianet Newsable

Dec 10, 2024

S&P 500 Edges Lower; AutoZone Posts Downbeat EarningsAutoZone (NYSE:AZO), Chimerix (NASDAQ:CMRX) - Benzinga

Dec 10, 2024

Chimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Cancer Therapy - Yahoo Finance

Dec 10, 2024

Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings - Benzinga

Dec 10, 2024

Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday? - AOL

Dec 10, 2024

S&P 500 Index (INX) QuotePress Release - The Globe and Mail

Dec 10, 2024

TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail

Dec 10, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Dec 10, 2024

Dow Falls 150 Points; Oracle Posts Downbeat Results - Benzinga

Dec 10, 2024

Chimerix Pursues FDA Approval for Dordaviprone - TipRanks

Dec 10, 2024

Pre-market Movers: CMRX, CPIX, PCSA, CRDF, VRAR… - RTTNews

Dec 10, 2024

Dec 09, 2024

Chimerix Shares Top 52-week Highs, Company Plans FDA Submission of Cancer Drug Dordaviprone - MarketWatch

Dec 09, 2024

Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End - The Manila Times

Dec 09, 2024

Chimerix to File FDA Application for Breakthrough Brain Cancer Drug with 28% Response Rate - StockTitan

Dec 09, 2024

Chimerix Stock Draws Heavy Retail Chatter After Landing Price-Target Hike On FDA Submission Plan For Cancer Drug - MSN

Dec 09, 2024

Dec 06, 2024

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 06, 2024

Chimerix Awards Key Stock Options to New Employees in Strategic Talent Acquisition Move - StockTitan

Dec 06, 2024

Dec 05, 2024

Chimerix (FRA:CXF) Shares Outstanding (EOP) : 89.94 Mil (As of Sep. 2024) - GuruFocus.com

Dec 05, 2024

Nov 28, 2024

CMRX (Chimerix) Financial Strength : 5 (As of Sep. 2024) - GuruFocus.com

Nov 28, 2024

Nov 25, 2024

Glioma Market Size in the 7MM is approximately USD 1,000 million in 2023, estimated DelveInsight - The Globe and Mail

Nov 25, 2024

Nov 24, 2024

CMRX (Chimerix) Debt-to-EBITDA : -0.01 (As of Sep. 2024) - GuruFocus.com

Nov 24, 2024

Nov 20, 2024

Chimerix (FRA:CXF) Change In Receivables : €-0.13 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Wedbush Reiterates Outperform Rating for Chimerix (NASDAQ:CMRX) - Defense World

Nov 20, 2024

Nov 18, 2024

Chimerix (NASDAQ:CMRX) Earns Outperform Rating from Wedbush - MarketBeat

Nov 18, 2024

Nov 17, 2024

Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update - MarketBeat

Nov 17, 2024

Nov 14, 2024

Chimerix updates officer severance plan, extends term - Investing.com

Nov 14, 2024

Nov 11, 2024

Chimerix (CMRX) Announces Updated Phase 2 Response Assessment of Dordaviprone - StreetInsider.com

Nov 11, 2024

Chimerix Cancer Drug Shows 28% Response Rate in Phase 2 Brain Tumor Trial | CMRX Stock News - StockTitan

Nov 11, 2024

Nov 09, 2024

Wedbush Reaffirms “Outperform” Rating for Chimerix (NASDAQ:CMRX) - Defense World

Nov 09, 2024

Chimerix, Inc. (NASDAQ:CMRX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Chimerix Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 09, 2024

Nov 08, 2024

Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 08, 2024

Earnings call: Chimerix reports progress and financials for Q3 2024 - Investing.com India

Nov 08, 2024